Imprimis Pharmaceuticals

Imprimis Pharmaceuticals is a publicly traded pharmaceutical company (NASDAQ: IMMY) based in San Diego.[1][2] It makes eye drops, compounded medicines and other products.

It manufactures a pyrimethamine and leucovorin compound which may offer a low-cost "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000% by Martin Shkreli and Turing Pharmaceuticals.[3][2]

Governance

In October 2015, Anthony Principi was elected to the company's board of directors.[4]

References

  1. ↑ "Imprimis Pharmaceuticals". imprimispharma.com. Impimis Pharma.
  2. 1 2 Bomey, Nathan (2015-10-23). "Drug company attempts $1 alternative to Daraprim". USA TODAY. Retrieved 2016-01-04.
  3. ↑ Kroll, David. "Imprimis' Fight Against Martin Shkreli Is Part Of A Larger Battle". Forbes. Forbes Publishing Group.
  4. ↑ Staff (1 October 2015). "People". Genetic Engineering & Biotechnology News (Paper). 35 (17). p. 49. Imprimis Pharmaceuticals elected Anthony J. Principi to its board of directors


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.